Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 7/20 | 0.68 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.68 |
| ▸ | CHUK | O15111 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.66 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | ILK | Q13418 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170886 | 0.85 | AKT2 (0.73) | AKT2KMT2AIKBKBMAP3K14CHUK | |
| SCHEMBL2322659 | 0.80 | AKT2 (0.67) | AKT2KMT2AIKBKBMAP3K14CHUK | |
| SCHEMBL13312276 | 0.79 | IKBKB (0.67) | AKT2KMT2AIKBKBMAP3K14CHUK | |
| SCHEMBL10166769 | 0.79 | MAPK1 (0.68) | AKT2KMT2ACHEK1MAPK1NPSR1 | |
| SCHEMBL873114 | 0.79 | AKT2 (1.00) | AKT2KMT2AIKBKBMAP3K14CHUK | |
| SCHEMBL9170900 | 0.78 | AKT2 (0.62) | AKT2KMT2AIKBKBMAP3K14CHUK | |
| SCHEMBL20723123 | 0.78 | AKT2 (0.63) | AKT2KMT2AIKBKBMAP3K14CHUK | |
| SCHEMBL5820038 | 0.78 | MAPK1 (1.00) | AKT2KMT2AMAPK1NPSR1L3MBTL1 | |
| SCHEMBL11192094 | 0.78 | AKT2 (0.68) | AKT2KMT2ACHEK1MAPK1NPSR1 | |
| SCHEMBL6132022 | 0.77 | MAPK1 (0.80) | AKT2KMT2AIKBKBMAP3K14CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021119343-A1 | COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ANALOGS AS INHIBITORS OF KRAS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3664806-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3110818-B1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2019032720-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032720-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-14 | — | — | WO | disclosed |
| CN-107074861-A | 9H pyrimido [4,5-B ] indoles and related analogs as BET bromodomain inhibitors | 密执安大学评议会 | 2017-08-18 | — | — | CN | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
| US-9580430-B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-02-28 | — | — | US | disclosed |
| EP-3110818-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | The Regents of The University of Michigan (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| CN-101035802-A | Inhibitors of IAP | GENENTECH INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778718-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014361-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | AKT2 3944/4885KMT2A 225/4885IKBKB 515/4885 |
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | AKT2 2270/4885KMT2A 3374/4885IKBKB 304/4885 |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | AKT2 3944/4885KMT2A 225/4885IKBKB 515/4885 |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | BIRC5, BIRC2, XIAP | AKT2 3018/4885KMT2A 2131/4885IKBKB 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.